An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2016
Affiliation
Department of Medicine, Stanford University, Palo Alto, California; gchertow@stanford.edu.; Renal Research Institute, New York, New York;; Cleveland Clinic Foundation, Cleveland, Ohio;; University of Illinois, Chicago, Illinois;; National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland;; Yale University, New Haven, Conneticut;; Cleveland Clinic Foundation, Cleveland, Ohio;; Wake Forest University, Winston-Slem, North Carolina; and.; Cleveland Clinic Foundation, Cleveland, Ohio; University of Utah, Salt Lake City, Utah.
Authors
Chertow Glenn M, Levin Nathan W, Beck Gerald J, Daugirdas John T, Eggers Paul W, Kliger Alan S, Larive Brett, Rocco Michael V, Greene Tom
Studies

Abstract

The Frequent Hemodialysis Network Daily Trial randomized 245 patients to receive six (frequent) or three (conventional) in-center hemodialysis sessions per week for 12 months. As reported previously, frequent in-center hemodialysis yielded favorable effects on the coprimary composite outcomes of death or change in left ventricular mass and death or change in self-reported physical health. Here, we determined the long-term effects of the 12-month frequent in-center hemodialysis intervention. We determined the vital status of patients over a median of 3.6 years (10%-90% range, 1.5-5.3 years) after randomization. Using an intention to treat analysis, we compared the mortality hazard in randomized groups. In a subset of patients from both groups, we reassessed left ventricular mass and self-reported physical health a year or more after completion of the intervention; 20 of 125 patients (16%) randomized to frequent hemodialysis died during the combined trial and post-trial observation periods in contrast to 34 of 120 patients (28%) randomized to conventional hemodialysis. The relative mortality hazard for frequent versus conventional hemodialysis was 0.54 (95% confidence interval, 0.31 to 0.93); with censoring of time after kidney transplantation, the relative hazard was 0.56 (95% confidence interval, 0.32 to 0.99). Bayesian analysis suggested a relatively high probability of clinically significant benefit and a very low probability of harm with frequent hemodialysis. In conclusion, a 12-month frequent in-center hemodialysis intervention significantly reduced long-term mortality, suggesting that frequent hemodialysis may benefit selected patients with ESRD.